Pharnext S.A. (Euronext Paris: ALPHA)

https://www.pharnext.com

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: pleotherapy. The Company identifies and develops synergic combinations of repositioned drugs at low dose. These “pleodrugs” offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team. The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code : FR00111911287). *

	Start	2007-05-22 established
	Predecessor	Pharnext SAS
	Industry	Pleotherapy™ technology
	Industry 2	drug repositioning services
	Person	Solomon, David Horn (Mithra Pharmaceuticals 202304– before Pharnext+ Silence Tx + Zealand Pharma + Bionor Pharma)
	Person 2	Cohen, Daniel (Pharnext 201601 CEO + Founder before Genset + Millennium Pharmaceuticals)

	Region	Issy-les-Moulineaux
	Country	France
	Street	11 rue des Peupliers
	City	92130 Issy-les-moulineaux
	Tel	+33-1-4109-2230
		Address record changed: 2024-01-05

Basic data	Employees	n. a.
	Currency	EUR
	Cash	6,149,000 (2017-06-30)

		* Document for »About Section«:

		Record changed: 2024-02-12